This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cytogenetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The diagnosis of APL is primarily based on the peripheral blood film and marrow aspirate, but cytogenetic studies will reveal that the vast majority of patients with APL have a balanced translocation between chromosomes 15 and 17 (t[15,17]).

The breakpoints for this translocation are highly conserved to two regions on chromosome 15 and a single region on 17. The 15 breakpoint disrupts a gene called pml which codes for a protein which is probably a transcription factor. The 17 breakpoint disrupts the gene for the retinoic acid receptor-alpha, which is a nuclear receptor (part of the steroid-thyroid superfamily).

t[15,17] results in a hybrid protein PML/RAR which blocks differentiation of the promyelocyte. The precise mechanism is unclear, but is most likely to be due to alteration of PML action. This is supported by immunofluorescence studies which show that the nuclear organisation of PML/RAR is different to that of PML. It is therefore postulated that the precise location of transcription factors in the nucleus affects their function, to the extent of blocking cell differentiation.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.